Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03794180 · ClinicalTrials.gov registry record · Phase 1
Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects
A Phase 1 study, sponsored by I-Mab Biopharma US Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT03794180 is a Phase 1 study that has completed, run by I-Mab Biopharma US Limited. The registered enrollment target is 32 participants.
The verdict
NCT03794180, a Phase 1 study, has completed, sponsored by I-Mab Biopharma US Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
TJ003234RAR101 is a first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled, single ascending dose study of TJ003234 in healthy adults to determine whether TJ003234 is safe and tolerated when administered as an intravenous (IV) infusion and to determine the maximum dose tolerated (MTD).
Interventions
- DRUG Placebo
- DRUG TJ003234
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-03-18 |
| Est. Completion | 2019-09-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03794180
The ClinicalTrials.gov registry entry for NCT03794180 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is I-Mab Biopharma US Limited, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03794180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03794180 about?
NCT03794180 is a clinical study titled "Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects". TJ003234RAR101 is a first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled, single ascending dose study of TJ003234 in healthy adults to determine whether TJ003234 is safe and tolerated when administered as an intravenous (IV) infusion and to determine the maximum dose tol...
What is the current status of trial NCT03794180?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2019-03-18. Estimated completion is 2019-09-05.
What interventions are being tested in trial NCT03794180?
The interventions under investigation include: Placebo (DRUG), TJ003234 (DRUG).
Who is sponsoring clinical trial NCT03794180?
This trial is sponsored by I-Mab Biopharma US Limited, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.